GraniteShares YieldBOOST CRCL ETF logo

GraniteShares YieldBOOST CRCL ETF (CRY)

Market Open
12 Aug, 16:19
NYSE NYSE
$
17. 46
-0.04
-0.2286%
$
963.27K Market Cap
0.12% Div Yield
430 Volume
$ 17.5
Previous Close
Add Transaction
Day Range
17.45 17.49
Year Range
17.21 25.93
Want to track CRY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CRY trading today lower at $17.46, a decrease of -0.2286% from yesterday's close, completing a monthly decrease of -10.5533% or -$2.06. Over the past 12 months, CRY stock lost -30.0481%.
CRY pays dividends to its shareholders, with the most recent payment made on Yesterday at 12:00 AM. The next estimated payment will be in 1 day ago on Yesterday at 12:00 AM for a total of $0.27371.
GraniteShares YieldBOOST CRCL ETF has completed 2 stock splits, with the recent split occurring on Dec 28, 2000.
The company's stock is traded on one exchange.

CRY Chart

People also search for

Annovis Bio, Inc.
$ 1.88
-0.2653%
Birchtech Corp.
$ 1.43
+4.3796%
Nuvation Bio Inc.
$ 0.07
-0.8568%
Babylon Holdings Limited
$ 0.55
-13.9866%
Cano Health, Inc.
$ 2.3
-2.1277%
Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript

Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript

Artivion, Inc. (NYSE:AORT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Suraj Kalia - Oppenheimer John McAulay - Stifel Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. And welcome to Artivion's Second Quarter 2024 Financial Conference Call.

Seekingalpha | 2 years ago
Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates

Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates

Artivion (AORT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.06 per share a year ago.

Zacks | 2 years ago
Data-Driven Growth Fuels More Upside For Overlooked Artivion

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts. Positive post-approval trial data for the On-X aortic valve and a successful PERSEVERE IDE study for AMDS hybrid prosthesis can drive additional revenue growth. A strong pipeline, including NEXUS and ARCEVO stent graft systems, can support a longer runway of continued revenue growth.

Seekingalpha | 2 years ago

GraniteShares YieldBOOST CRCL ETF (CRY) FAQ

What is the stock price today?

The current price is $17.46.

On which exchange is it traded?

GraniteShares YieldBOOST CRCL ETF is listed on NYSE.

What is its stock symbol?

The ticker symbol is CRY.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.12%.

What is its market cap?

As of today, the market cap is 963.27K.

Has GraniteShares YieldBOOST CRCL ETF ever had a stock split?

GraniteShares YieldBOOST CRCL ETF had 2 splits and the recent split was on Dec 28, 2000.

GraniteShares YieldBOOST CRCL ETF Profile

NYSE Exchange
US Country

Overview

Artivion, Inc., initially known as CryoLife, Inc., before its name change in January 2022, is a prominent entity in the medical devices and implantable human tissues sector, with operations extending globally. Founded in 1984 and based in Kennesaw, Georgia, the company is adept at manufacturing, processing, and distributing a wide array of medical devices. These products are designed for use in various medical procedures, including cardiac, vascular, neurologic, and pulmonary operations. Artivion, Inc. caters to a diverse clientele, including physicians, hospitals, and other healthcare facilities, with its offerings significantly influencing the practices of cardiac, vascular, thoracic, and general surgeons across the world.

Products and Services

  • BioGlue: A unique polymer made from bovine blood protein, used across a range of surgical procedures for protein cross-linking.
  • Cardiac Preservation Services: Specialized services aimed at maintaining cardiac health during surgery.
  • PhotoFix: A bovine pericardial patch favored for its durability and versatility in surgical applications.
  • Aortic Arch Stent Grafts (E-vita Open Plus and E-vita Open Neo): Advanced solutions for complicated aortic surgeries, offering custom-designed options to meet specific patient needs.
  • E-xtra Design Engineering Systems: Tailored engineering solutions for tackling aortic vascular diseases effectively.
  • E-nside: An off-the-shelf stent graft designed for the thoraco-abdominal disease treatment, simplifying complex procedures.
  • E-vita THORACIC 3G: A cutting-edge endovascular solution for thoracic aortic aneurysm treatments, highlighting technological advancements in this field.
  • E-ventus BX: A balloon-expandable peripheral stent graft designed for the precise treatment of renal and pelvic arteries.
  • E-liac and E-tegra: Stent graft systems focused on treating aneurysmal conditions in iliac arteries and infrarenal abdominal aortic aneurysms, respectively, enhancing the range of vascular interventions available.
  • Synthetic Vascular Grafts: Synthetically engineered grafts for open aortic and peripheral vascular surgical procedures, exemplifying the advancements in synthetic biocompatible materials.
  • PerClot: An absorbable powdered hemostat used in various surgical interventions to promote hemostasis efficiently.
  • Cardiac Laser Therapy Products: Innovative solutions for angina treatment, using laser technology to provide relief and improve patient outcomes.
  • CryoVein and CryoArtery: Vascular preservation services for femoral veins and arteries, enhancing the longevity and success rates of vascular surgeries.
  • On-X Prosthetic Heart Valves (Aortic and Mitral) and Ascending Aortic Prosthesis: State-of-the-art artificial heart valves and associated prostheses for cardiac surgery, representing significant achievements in materials science and biomechanics.
  • CarbonAid CO2 Diffusion Catheters and Chord-X ePTFE Sutures: Advanced catheter systems for CO2 management and high-quality sutures for mitral chordal replacement, illustrating the precision manufacturing techniques used in medical devices.
  • Ascyrus Medical Dissection Stents: Specialized stents designed for the treatment of arterial dissections, contributing to safer cardiovascular procedures.
  • Pyrolytic Carbon Coating Services: Specialized services offered to other medical device manufacturers, highlighting Artivion, Inc.’s capacity for innovation and support within the medical device manufacturing industry.

Contact Information

Address: 205 Hudson Street, 7th Floor
Phone: 770 419 3355